Millennium Management LLC Acquires 708,857 Shares of Fresenius Medical Care AG (NYSE:FMS)

Millennium Management LLC boosted its position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 5,297.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 722,238 shares of the company's stock after purchasing an additional 708,857 shares during the period. Millennium Management LLC owned about 0.12% of Fresenius Medical Care worth $16,351,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in FMS. Venturi Wealth Management LLC increased its holdings in shares of Fresenius Medical Care by 8.4% during the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after buying an additional 441 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Fresenius Medical Care by 5.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,278 shares of the company's stock worth $210,000 after acquiring an additional 442 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after acquiring an additional 806 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in Fresenius Medical Care by 1.5% during the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock valued at $1,316,000 after purchasing an additional 862 shares in the last quarter. Finally, Signaturefd LLC raised its position in Fresenius Medical Care by 16.6% in the 4th quarter. Signaturefd LLC now owns 7,393 shares of the company's stock valued at $167,000 after purchasing an additional 1,052 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care Price Performance

Shares of Fresenius Medical Care stock traded up $0.64 during midday trading on Tuesday, reaching $29.66. The company had a trading volume of 122,989 shares, compared to its average volume of 326,549. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $25.61 and a 200 day simple moving average of $24.09. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $30.46. The company has a market capitalization of $17.41 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. As a group, equities research analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Increases Dividend

The company also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be issued a $0.7871 dividend. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. Fresenius Medical Care's dividend payout ratio (DPR) is currently 49.11%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on FMS. Morgan Stanley reissued an "underweight" rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. Wall Street Zen began coverage on shares of Fresenius Medical Care in a research report on Tuesday, May 20th. They set a "strong-buy" rating on the stock. Finally, Truist Financial increased their price objective on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $27.80.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.